AI Stock Monitor
AMGN - Amgen
Amgen is a North America covered company in The Hedge Book research universe.
Public company · North America · Healthcare · Biotechnology · Dow constituent
0 followers · Follow to include this stock in your daily 9:30 AM Central watchlist email.
NASDAQ · Healthcare · Research updated · Market data updated Research and source refreshes run four times daily. The timestamps above identify the latest successful research and market-data updates.
Hedge Score
70
/100
Price History
AMGN chart
AI-Assisted Chart Analysis
Amgen technical analysis
Calculated from verified chart history for the selected tenor; no news or fundamental assumptions are used.
Constructive uptrend: the latest level is above the 50-period average and the 50-period average is above the 200-period average.
RSI is 77, a extended reading. Above 70 can signal extension; below 30 can signal exhaustion.
The first technical watch zone is 326.31. A break below 272.98 invalidates the near-term support setup.
The first resistance/watch zone is 417.20. A confirmed break above 417.20 supports continuation.
Annualized realized volatility is +53.7%. Maximum lookback drawdown is -24.5%, from a high-water mark of 287.29 to 216.93.
Potential levels are conditional chart scenarios, not personalized advice or instructions to buy or sell.
How To Read This Stock Brief
Higher means the current research setup is stronger across signal, confidence, catalysts, risk balance, and market context. Lower means the setup is weaker or less supported.
Higher confidence means the evidence is more consistent and relevant. It does not mean the stock has that percentage chance of going up.
Bullish, Bearish, or Neutral is the current AI research stance. It is designed to help you ask better questions, not to replace your decision process.
This shows how signed-in users are voting. It is useful sentiment context, not proof that the crowd is right.
What Changed Today
- Yahoo Finance delayed market data reported AMGN at 417.20 USD; the latest daily move rose +1.52%. This is a verified market-price signal only and does not by itself confirm a change in company fundamentals.
Why It Matters
- The verified +1.52% daily move is current market context for Amgen.
- It can affect near-term sentiment, but price action alone does not establish a change in earnings, asset quality, competitive position, valuation, catalysts, or risks.
- Those require a separately sourced filing or company update.
AI Opinion
- Read: The overall outlook is bullish, supported by robust Q2 financial results and an upward revision to full-year guidance, which has prompted analyst target price increases.
- Evidence: Amgen's ability to deliver double-digit revenue growth while navigating a competitive landscape demonstrates resilience in its core cardiovascular and rare-disease franchises.
- Uncertainty: The discontinuation of the early-stage obesity drug is a prudent move that likely improves R&D efficiency, though it removes a potential long-term growth lever.
- Watch: Investors should monitor the fallout from the reported data breach, as regulatory scrutiny or litigation could create unforeseen headwinds despite the strong fundamental performance.
Key Risks
- The reported cybersecurity breach involving patient data could lead to significant regulatory fines, litigation costs, and reputational damage that may weigh on future earnings.
- Continued reliance on legacy products, despite current growth in newer drugs, poses a risk if biosimilar competition accelerates faster than anticipated.
- The discontinuation of AMG 513 highlights the inherent uncertainty in the drug development pipeline, where failure of late-stage candidates could significantly impact long-term valuation.
- Macroeconomic or regulatory pressures on drug pricing could compress profit margins, potentially offsetting the gains achieved through volume growth.
Upcoming Catalysts
- Future earnings reports will be critical to confirm if the raised guidance is sustainable and if the growth in key products like Repatha continues to outpace legacy portfolio declines.
- Updates regarding the investigation into the patient data breach, including any potential legal or regulatory settlements, will be necessary to quantify the financial impact.
- Clinical trial readouts for the remaining late-stage pipeline will serve as the primary driver for long-term valuation expansion, as the company seeks to replace aging assets.
- Strategic capital allocation decisions, such as potential M&A activity or share buybacks, could further influence shareholder returns and balance sheet strength.
Upcoming Events
No verified update available
Last Updated
Sources and verification
Each generated research claim remains linked to its supporting update. Primary evidence comes from filings, company materials, or regulators; secondary evidence provides additional context.
- Published stock briefSecondary sourceReportedAmgen Inc. (AMGN) Stock Price, News, Quote & History - Yahoo! Finance Canada · Published 2026-08-10 09:01:29Open verification sourceSupports: Published stock brief
- Published stock briefSecondary sourceReportedAmgen (AMGN) Stock Sees Fair Value Lift After Q2 Beat And Analyst Target Hikes · Published 2026-08-10 09:01:29Open verification sourceSupports: Published stock brief
- Published stock briefSecondary sourceReportedHow a 52-Year-Old Can Turn $425,000 Into a Monthly Paycheck Machine by 62 · Published 2026-08-10 09:01:29Open verification sourceSupports: Published stock brief
- Published stock briefSecondary sourceReportedThe 4% Rule vs. a Dividend Paycheck: Which Makes $1.25 Million Last Longer? · Published 2026-08-10 09:01:29Open verification sourceSupports: Published stock brief
- Published stock briefSecondary sourceReportedReplimune Wins FDA Skin Cancer Drug Approval on Third Try. Why the Stock Is Tumbling. · Published 2026-08-10 09:01:29Open verification sourceSupports: Published stock brief
Market-data attributionYahoo Finance delayed market data · provider detailsMarket prices are supporting signals only and do not establish the research conclusion.
Community View
Sign in with Google to vote once per stock.
Total votes: 0
Disclaimer
The Hedge Book provides AI-assisted educational market research. It is not a registered investment adviser, broker, dealer, or financial planner. Content may contain errors and should be independently verified. Do not treat this page as personalized advice to buy, sell, or hold any security.